168 related articles for article (PubMed ID: 34397130)
21. Sequential design of phase II-III cancer trials.
Lai TL; Lavori PW; Shih MC
Stat Med; 2012 Aug; 31(18):1944-60. PubMed ID: 22422502
[TBL] [Abstract][Full Text] [Related]
22. Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learned.
Yao JC; Lagunes DR; Kulke MH
Oncologist; 2013; 18(5):525-32. PubMed ID: 23615698
[TBL] [Abstract][Full Text] [Related]
23. Improving the design of phase II trials of cytostatic anticancer agents.
Stone A; Wheeler C; Barge A
Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours.
Raymond E; Kulke MH; Qin S; Yu X; Schenker M; Cubillo A; Lou W; Tomasek J; Thiis-Evensen E; Xu JM; Croitoru AE; Khasraw M; Sedlackova E; Borbath I; Ruff P; Oberstein PE; Ito T; Jia L; Hammel P; Shen L; Shrikhande SV; Shen Y; Sufliarsky J; Khan GN; Morizane C; Galdy S; Khosravan R; Fernandez KC; Rosbrook B; Fazio N
Neuroendocrinology; 2018; 107(3):237-245. PubMed ID: 29991024
[TBL] [Abstract][Full Text] [Related]
25. Randomized, controlled clinical trials in sepsis: has methodological quality improved over time?
Graf J; Doig GS; Cook DJ; Vincent JL; Sibbald WJ
Crit Care Med; 2002 Feb; 30(2):461-72. PubMed ID: 11889331
[TBL] [Abstract][Full Text] [Related]
26. Quality of life in patients with gastroenteropancreatic tumours: A systematic literature review.
Watson C; Tallentire CW; Ramage JK; Srirajaskanthan R; Leeuwenkamp OR; Fountain D
World J Gastroenterol; 2020 Jul; 26(25):3686-3711. PubMed ID: 32742136
[TBL] [Abstract][Full Text] [Related]
27. Statistics in clinical trials.
Green SJ; Pauler DK
Curr Oncol Rep; 2004 Jan; 6(1):36-41. PubMed ID: 14664759
[TBL] [Abstract][Full Text] [Related]
28. Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials.
Pond GR; Abbasi S
Clin Trials; 2011 Jun; 8(3):260-9. PubMed ID: 21511687
[TBL] [Abstract][Full Text] [Related]
29. Statistical aspects of the TNK-S2B trial of tenecteplase versus alteplase in acute ischemic stroke: an efficient, dose-adaptive, seamless phase II/III design.
Levin B; Thompson JL; Chakraborty B; Levy G; MacArthur R; Haley EC
Clin Trials; 2011 Aug; 8(4):398-407. PubMed ID: 21737464
[TBL] [Abstract][Full Text] [Related]
30. Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study.
Martín-Richard M; Massutí B; Pineda E; Alonso V; Marmol M; Castellano D; Fonseca E; Galán A; Llanos M; Sala MA; Pericay C; Rivera F; Sastre J; Segura A; Quindós M; Maisonobe P;
BMC Cancer; 2013 Sep; 13():427. PubMed ID: 24053191
[TBL] [Abstract][Full Text] [Related]
31. Optimizing the data combination rule for seamless phase II/III clinical trials.
Hampson LV; Jennison C
Stat Med; 2015 Jan; 34(1):39-58. PubMed ID: 25315892
[TBL] [Abstract][Full Text] [Related]
32. SOP 09: Statistical design and analysis.
Onkologie; 2003 Oct; 26 Suppl 6():43-7. PubMed ID: 23570186
[No Abstract] [Full Text] [Related]
33. Setting the bar in phase II trials: the use of historical data for determining "go/no go" decision for definitive phase III testing.
Vickers AJ; Ballen V; Scher HI
Clin Cancer Res; 2007 Feb; 13(3):972-6. PubMed ID: 17277252
[TBL] [Abstract][Full Text] [Related]
34. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.
Yao JC; Fazio N; Singh S; Buzzoni R; Carnaghi C; Wolin E; Tomasek J; Raderer M; Lahner H; Voi M; Pacaud LB; Rouyrre N; Sachs C; Valle JW; Fave GD; Van Cutsem E; Tesselaar M; Shimada Y; Oh DY; Strosberg J; Kulke MH; Pavel ME;
Lancet; 2016 Mar; 387(10022):968-977. PubMed ID: 26703889
[TBL] [Abstract][Full Text] [Related]
35. Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency.
Elsäßer A; Regnstrom J; Vetter T; Koenig F; Hemmings RJ; Greco M; Papaluca-Amati M; Posch M
Trials; 2014 Oct; 15():383. PubMed ID: 25278265
[TBL] [Abstract][Full Text] [Related]
36. A modified varying-stage adaptive phase II/III clinical trial design.
Dong G; Vandemeulebroecke M
Pharm Stat; 2016 Jul; 15(4):368-78. PubMed ID: 27264007
[TBL] [Abstract][Full Text] [Related]
37. A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve.
Wilson MK; Friedlander ML; Joly F; Oza AM
Oncologist; 2018 Feb; 23(2):203-213. PubMed ID: 29118265
[TBL] [Abstract][Full Text] [Related]
38. Randomized phase II trials: a long-term investment with promising returns.
Sharma MR; Stadler WM; Ratain MJ
J Natl Cancer Inst; 2011 Jul; 103(14):1093-100. PubMed ID: 21709274
[TBL] [Abstract][Full Text] [Related]
39. Methodology of phase II clinical trials in metastatic elderly breast cancer: a literature review.
Cabarrou B; Mourey L; Dalenc F; Balardy L; Kanoun D; Roché H; Boher JM; Rougé-Bugat ME; Filleron T
Breast Cancer Res Treat; 2017 Aug; 164(3):505-513. PubMed ID: 28488143
[TBL] [Abstract][Full Text] [Related]
40. Satraplatin: BMS 182751, BMY 45594, JM 216.
Drugs R D; 2007; 8(2):125-32. PubMed ID: 17324011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]